"Initially, ResApp will focus on introducing it into clinical trial settings to measure cough frequency"
The only "clinical trial setting to measure cough frequency" that I'm aware of is the Astrazeneca trial in Japan monitoring lung cancer patients. That trial is going to allow the company to place maybe an armload of devices at cost. Not very encouraging.
Hopefully (implying that I have hope without expectation) they will be able to leverage that into demonstrations of utility in a clinical setting and finally get some action.
RAP Price at posting:
5.7¢ Sentiment: Hold Disclosure: Held
